Multiple Myeloma: all 3,712 studies

Page 21 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple MyelomaTerminatedNCT04855136Phase 1
• Patient Reported Outcomes and Patient Education in Cellular Therapy PatientsCompletedNCT04853277Not applicable
• Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04850599Phase 2
• A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)CompletedNCT04840680
• Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT04835129Phase 2
• Covid-19 Vaccine Responsiveness in MM and WaldenstromCompletedNCT04830046
• Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive CarfilzomibTerminatedNCT04827563
• Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaActive, not recruitingNCT04822337Phase 1/2
• Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaStatus unknownNCT04818372Phase 1
• Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma CellsCompletedNCT04813653Phase 1
• A Dose Escalation Study of LNA-i-Mir-221 for Cancer TreatmentCompletedNCT04811898Phase 1
• Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate UseCompletedNCT04811508
• Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04808037Phase 1/2
• Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple MyelomaTerminatedNCT04805203Not applicable
• Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma PatientsActive, not recruitingNCT04802356Phase 2
• Rapid-infusion Isatuximab in Relapsed/Refractory Multiple MyelomaWithdrawnNCT04802031Phase 2
• Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and BortezomibActive, not recruitingNCT04790474Phase 2
• A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMMActive, not recruitingNCT04786028Phase 2
• Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma PatientsCompletedNCT04783038Not applicable
• Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04782687Phase 2
• DARA RVD For High Risk SMMActive, not recruitingNCT04775550Phase 2
• A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT04773522Phase 1
• A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesCompletedNCT04772989Phase 1
• Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE TrialActive, not recruitingNCT04764942Phase 1/2
• The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple MyelomaStatus unknownNCT04762745Phase 1/2
• The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple MyelomaCompletedNCT04760405Not applicable
• Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in SwedenCompletedNCT04760184
• CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple MyelomaCompletedNCT04758767Phase 1
• Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaActive, not recruitingNCT04756726Phase 1
• agenT-797 in Participants With Relapsed/Refractory Multiple MyelomaCompletedNCT04754100Phase 1
• Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).Active, not recruitingNCT04751877Phase 3
• The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19Status unknownNCT04746092
• A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaTerminatedNCT04735575Phase 1/2
• A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MMTerminatedNCT04730505Phase 1
• MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) SurveyStatus unknownNCT04727294
• A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingNCT04722146Phase 1
• Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)CompletedNCT04721002
• NXC-201 (formerly HBI0101) Multiple MyelomaActive, not recruitingNCT04720313Phase 1
• Heart Rate Variability, Vagus Nerve and CancerTerminatedNCT04718610Not applicable
• Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM PatientsActive, not recruitingNCT04717700Phase 2
• Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients Treated With Chemotherapy for Haematological CancerTerminatedNCT04716153Not applicable
• Novel BCMA-targeted CAR-T Cell Therapy for Multiple MyelomaStatus unknownNCT04706936Phase 1
• VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)TerminatedNCT04702425Phase 1
• A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma PatientsStatus unknownNCT04688853Phase 1
• Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCTWithdrawnNCT04685525Not applicable
• SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruitingNCT04684108Phase 1
• A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.CompletedNCT04683393
• Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omicsStatus unknownNCT04678089
• A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT04674813Phase 1
• APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Phase 1/2
• Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT04671251Phase 1
• CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.Active, not recruitingNCT04667663Phase 1
• A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life PracticeCompletedNCT04659798
• CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19)Status unknownNCT04659252
• Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First RelapseActive, not recruitingNCT04656951Phase 2
• Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMMActive, not recruitingNCT04653246Phase 2
• Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen ReceptorCompletedNCT04650724Early Phase 1
• Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT04649073Phase 1/2
• Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaCompletedNCT04640779Phase 1
• Anti-BCMA CAR-T Cell Therapy for the R/R Multiple MyelomaStatus unknownNCT04637269Early Phase 1
• Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple MyelomaActive, not recruitingNCT04635189Phase 2
• Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma PatientsCompletedNCT04634435Phase 1
• Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCTCompletedNCT04629430Not applicable
• CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04626752Early Phase 1
• Observational Study of Home Administration of CarfilzomibWithdrawnNCT04621955
• BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple MyelomaStatus unknownNCT04617704Early Phase 1
• Screening to Improve Survival in AL AmyloidosisCompletedNCT04615572
• FT538 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04614636Phase 1
• Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04613557Phase 1
• Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI)Status unknownNCT04609150
• Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer PatientsCompletedNCT04604158Not applicable
• A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple MyelomaStatus unknownNCT04601935Phase 1
• Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing TransplantationCompletedNCT04589286Not applicable
• A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04586426Phase 1/2
• Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous TransplantWithdrawnNCT04584307Phase 2
• ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple MyelomaWithdrawnNCT04579523Phase 1
• Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT04570631Phase 1
• Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM PatientsActive, not recruitingNCT04564703Phase 2
• Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple MyelomaActive, not recruitingNCT04561492Phase 2
• Clinical Study of Autologous Natural Killer Cells in Multiple MyelomaStatus unknownNCT04558853Phase 1
• A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)CompletedNCT04557150Phase 1
• MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple MyelomaActive, not recruitingNCT04555551Phase 1
• The clonoSEQ® Watch RegistryTerminatedNCT04545333
• A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic MalignanciesCompletedNCT04543305Phase 1
• Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST StudyActive, not recruitingNCT04537871
• Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04537442Phase 1
• Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple MyelomaApproved for marketingNCT04534322
• Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple MyelomaCompletedNCT04530812Not applicable
• Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple MyelomaTerminatedNCT04521335Phase 1
• Novel Drugs After Allo-HSCT in Patients With Multiple MyelomaCompletedNCT04506320
• Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple MyelomaSuspendedNCT04505813Phase 1/2
• Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MMStatus unknownNCT04500431Phase 1
• A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple MyelomaActive, not recruitingNCT04499339Phase 1/2
• A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or LenalidomideActive, not recruitingNCT04497961Phase 2
• Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell TransplantationStatus unknownNCT04496011Not applicable
• Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRITerminatedNCT04493411Not applicable
• COVID-19 Infection and Multiple MyelomaCompletedNCT04492371
• Virtual Exercise for Multiple MyelomaCompletedNCT04484714Not applicable
• Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)Active, not recruitingNCT04483739Phase 3
• A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With MyelomaWithdrawnNCT04467281Phase 2

← Multiple Myeloma overview